63
Participants
Start Date
August 31, 2000
Primary Completion Date
April 30, 2009
Study Completion Date
April 30, 2010
Autologous hematopoietic cell transplant (Auto-HCT)
The target cell dose is 2.6 x 10e6 CD34+ cells/kg
Allogeneic hematopoietic cell transplant (Allo-HCT)
The target cell dose is 5 x 10e6 CD34 cells/kg
Cyclophosphamide
Cyclophosphamide administered intravenously (IV) at 4 mg /m² mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion
Filgrastim
"* Filgrastim 10 µg/kg/day to mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion (Auto-HCT)~* Filgrastim 5 µg/kg/day starting 6 days after melphalan (Day 4 after Auto-HCT)~* Filgrastim 16 µg/kg/day to mobilize donor peripheral blood progenitor cells (PBPC) for allogeneic transplant (Allo-HCT)"
Melphalan
Melphalan 200 mg/m2 (high-dose) intravenously as conditioning for Auto-HCT
Total body irradiation (TBI)
200 centigray (cGy) total body irradiation delivered on Day 0
Cyclosporine (CSP)
Cyclosporine administered twice-daily by mouth at a dose of 6.25 mg/kg from Day -3 through Day 56
Mycophenolate Mofetil (MMF)
Mycophenolate mofetil will begin at 15 mg/kg twice-daily by mouth from Day 0 to Day 27
Stanford University School of Medicine, Stanford
Wen-Kai Weng
OTHER